News stories about Pacific Biosciences of California (NASDAQ:PACB) have trended positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a news impact score of 0.38 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.3962583245601 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- PacBio’s Library Preparation Issues Announced At A Tough Time – Seeking Alpha (seekingalpha.com)
- Pacific Biosciences Hurt by Competition in Niche Markets (finance.yahoo.com)
- Pacific Biosciences of California (PACB) and Viewray (VRAY) Financial Survey (americanbankingnews.com)
- Pacific Biosciences of California (PACB) Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
Pacific Biosciences of California (NASDAQ PACB) traded up $0.20 during trading hours on Friday, hitting $2.72. The company had a trading volume of 1,521,526 shares, compared to its average volume of 1,090,000. The company has a quick ratio of 3.15, a current ratio of 3.75 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $316.20, a P/E ratio of -2.99 and a beta of 1.75. Pacific Biosciences of California has a 12 month low of $2.51 and a 12 month high of $5.74.
A number of equities research analysts recently commented on PACB shares. BidaskClub downgraded Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research report on Saturday. Zacks Investment Research downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Tuesday. CL King downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 target price on the stock. in a research report on Thursday, September 28th. Finally, First Analysis downgraded Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 target price on the stock. in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.27.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.